"Designing Growth Strategies is in our DNA"

U.S. Anti-Inflammatory Biologics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitor, and Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route of Administration (Oral and Injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country Forecast, 2023-2030

Last Updated: June 24, 2024 | Format: PDF | Report ID: FBI109142

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The U.S. anti-inflammatory biologics market size was worth USD 51.57 billion in 2022 and is projected to grow at a CAGR of 6.1% during the forecast period. 


Anti-inflammatory biologics are manufactured targeting specific inflammatory cells, cytokines, and cellular interactions mediating inflammatory-related tissue damage. The U.S. has observed a significant rise in the prevalence of inflammation-related diseases, which has increased the number of adults seeking treatment for these diseases. For instance, according to the CDC, in the U.S., the prevalence of asthma was 24,963,874 in 2021.


The surge in the introduction of drugs, strong healthcare infrastructure, growing focus of market players in the development of drugs, and the increasing geriatric population in the country drives the growth in the adoption of anti-inflammatory biologics.


The COVID-19 pandemic increased the adoption of these biologics by doctors in the country. The positive growth was attributed to the increase in patients with psoriasis and other inflammation disorders.


U.S. Anti-Inflammatory Biologics Market Trends


Strong Focus on Development of Novel Anti-inflammatory Biologics to Drive Market Expansion


In recent years, the market has witnessed a growing shift from traditional drugs to biologics due to the various benefits associated with these biologics. Furthermore, the key players focus on developing biologics to treat various chronic conditions, such as arthritis and multiple sclerosis, to attract a wider customer base.


In March 2023, Incyte announced new results of 104-week from the pivotal Phase 3 TRuE-V clinical trial program evaluating Opzelura (ruxolitinib) cream in adult patients 12 years of age and older suffering from nonsegmental vitiligo at the 2023 American Academy of Dermatology (AAD) Annual Meeting.


U.S. Anti-Inflammatory Biologics Market Growth Factors


Surging Inflammatory Diseases Incidence to Boost the Demand for Anti-inflammatory Biologics


The growing burden of inflammatory diseases, such as ulcerative colitis, rheumatoid arthritis, and psoriasis, has increased the demand for biologics in the U.S. anti-inflammatory biologics market. Furthermore, the swift utilization of biologics in terms of inflammatory disease treatment coupled with improved reimbursement trends for therapies with biologics is projected to fuel the market's growth. 



  • For instance, according to a study published by NCBI in June 2021, the estimated prevalence of adult psoriasis in the U.S. was 7.6 million. Such a large population suffering from psoriasis is expected to boost the U.S. anti-inflammatory biologics market growth.


RESTRAINING FACTORS


Limited Preference for Anti-Inflammatory Biologics as the Initial Treatment to Impede the Adoption of These Drugs


Despite the high effectiveness of biologics in rheumatoid arthritis and psoriasis treatment, the lack of inclination for biologics compared to disease-modifying anti-rheumatic drugs (DMARDs) hampers the market growth of anti-inflammatory biologics in the U.S.


For the treatment of rheumatoid arthritis, disease-modifying anti-rheumatic drugs (DMARDs), which include drugs, such as methotrexate, are considered the first-line treatment. Similarly, topical drugs for psoriasis, including corticosteroids and vitamin D analogues, are used as first-line treatment.



  • For instance, according to the Arthritis Foundation, in September 2022, the American College of Rheumatology recommended methotrexate over anti-inflammatory biologic as the first-line treatment for most individuals suffering from inflammatory autoimmune diseases, including rheumatoid arthritis and psoriatic arthritis.


Similarly, these drugs are used as a third line of treatment for rheumatoid and psoriatic arthritis. This is anticipated to substantially restrict the available patient pool for treatment, leading to the U.S. anti-inflammatory biologics market restraint in the forecast period.


Request a Free sample to learn more about this report.


U.S. Anti-Inflammatory Biologics Market Segmentation Analysis


By Drug Class Analysis


Based on the drug class, the market is segmented into anti-tumor necrosis factor (TNF), interleukin antagonists, janus kinase (JAK) inhibitor, and others.


The interleukin antagonists segment held the largest share and is anticipated to grow at a significant CAGR during the forecast period due to the rising prevalence of psoriasis and ulcerative colitis and increased patient visits to hospitals. Furthermore, the increased focus of market players on the research and development of Interleukin Inhibitors is expected to contribute to the segmental growth.



  • For instance, Pfizer is developing a biologics, Dekavil (F8IL10). It is a fully human anti-inflammatory product consisting of the F8 antibody fused to interleukin-10 (IL10). The drug is currently in Phase II of its clinical trial.


By Application Analysis


Based on application, the market is divided into psoriasis, rheumatoid arthritis, and others.


The rheumatoid arthritis segment held the highest market share in 2022. The highest share is due to the growing cases of rheumatoid arthritis across the country and the growing focus of market players to develop more anti-inflammatory biologics for this indication.



  • For instance, in October 2022, GSK plc provided an update on the ContRAst phase III programme for otilimab, an investigational monoclonal antibody in the potential treatment of moderate to severe rheumatoid arthritis. The ContRAst phase IIl programme enrolled a broad range of difficult-to-treat patients who had an inadequate response to available treatments.


By Route of Administration Analysis


By route of administration, the market for anti-inflammatory biologics is segmented into oral and injection. The injection segment is further sub-segmented into intravenous and subcutaneous segments.


The injection segment held the highest U.S. anti-inflammatory biologics market share in 2022. The growth is attributed to the maximum number of anti-inflammatory biologics administrated via subcutaneous or intravenous route, which is the primary reason for the dominant share of this segment.


By Distribution Channel Analysis


Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.


The hospital pharmacies segment held the largest share and is expected to grow at a robust CAGR during the forecast period owing to the presence of a large patient population seeking treatment for inflammation-related disorders in hospitals, which increases the demand for drugs in hospital pharmacies. Furthermore, rising incidences and cases of rheumatoid arthritis is expected to boost the market in the forecast period.


List of Key Companies in U.S. Anti-Inflammatory Biologics Market


In terms of the competitive landscape, the market for anti-inflammatory biologics depicts the presence of established and emerging companies operating in the market. Leading players in the market, such as AbbVie Inc. and Johnson & Johnson Services, Inc., have a significant share. AbbVie Inc. is one of the prominent players in the market solely from the sales of an anti-tumor necrosis factor (TNF) product called Humira.


Some other companies with a considerable presence in the U.S. anti-inflammatory biologics market include Amgen Inc., Eli Lilly and Company, Pfizer Inc. and other small & medium-sized players. These companies are focusing on introducing and developing novel drugs in the market, which is expected to boost their market share.


An Infographic Representation of U.S. Anti-Inflammatory Biologics Market

To get information on various segments, share your queries with us



LIST OF KEY COMPANIES PROFILED:



KEY INDUSTRY DEVELOPMENTS:



  • October 2023: The U.S. FDA announced the approval of BIMZELX (bimekizumab-bkzx) for treating moderate-to-severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy.

  • September 2022: Bristol Myers Squibb announced two-year results from the POETYK PSO long-term extension (LTE) trial with continuous Sotyktu treatment in adult patients with plaque psoriasis.

  • January 2022: AbbVie announced the U.S. FDA had approved RINVOQ for treating moderate to severe atopic dermatitis.


REPORT COVERAGE


The U.S. anti-inflammatory biologics market research report provides a detailed market analysis. The report provides information related to key industry developments such as mergers and acquisitions, and market dynamics. Additionally, it includes pipeline analysis, patent snapshot, and the epidemiology of key inflammatory disorders in the country. In addition, the impact of COVID-19 and the industry overview during the pandemic and post-pandemic are covered in the report.


To gain extensive insights into the market, Request for Customization


Report Scope & Segmentation



















































ATTRIBUTE



DETAILS



Study Period



2019-2030



Base Year



2022



Estimated Year



2023



Forecast Period



2023-2030



Historical Period



2019-2021



Growth Rate



CAGR of 6.1% from 2023 to 2030



Unit



Value (USD Billion)



Segmentation



By Drug Class



  • Anti-Tumor Necrosis Factor (TNF)

  • Interleukin Antagonists

  • Janus Kinase (JAK) Inhibitors

  • Others



By Application



  • Rheumatoid Arthritis

  • Psoriasis

  • Others



By Route of Administration



  • Oral

  • Injection

    • Intravenous

    • Subcutaneous





By Distribution Channel



  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies






Frequently Asked Questions

Fortune Business Insights says that the U.S. market was worth USD 51.57 billion in 2022.

The market is expected to exhibit a CAGR of 6.1% during the forecast period (2023-2030).

By drug class, the interleukin antagonists segment is leading the market.

AbbVie Inc. and Johnson & Johnson Services, Inc. are the top players in the market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • 2019-2030
  • 2022
  • 2019-2021
  • 80

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X